IGI Logo

Emcure Pharmaceuticals is currently trading at Rs. 1909.50, up by 48.80 points or 2.62% from its previous closing of Rs. 1860.70 on the BSE.

The scrip opened at Rs. 1870.15 and has touched a high and low of Rs. 1919.55 and Rs. 1861.75 respectively. So far 15904 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1944.00 on 25-Jun-2026 and a 52 week low of Rs. 1260.10 on 30-Sep-2025.

Last one week high and low of the scrip stood at Rs. 1,921.00 and Rs. 1,751.00 respectively. The current market cap of the company is Rs. 36134.07 crore.

The promoters holding in the company stood at 77.87%, while Institutions and Non-Institutions held 9.46% and 12.69% respectively.

Emcure Pharmaceuticals has secured Central Drugs Standard Control Organization's (CDSCO) approval to market Poviztra for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2-F3). The Poviztra is Emcure’s co-marketed brand of innovator semaglutide (rDNA origin). It enables Emcure and its subsidiaries to offer the new indication through Poviztra, expanding access to innovator semaglutide for patients living with a progressive liver disease that has long faced limited treatment options.

Poviztra contains innovator semaglutide (rDNA-origin) that has already established its role in chronic weight management in persons living with obesity and are overweight with co-morbid conditions (example Hypertension, Dyslipedemia, Type 2 Diabetes,etc). Poviztra is also approved and marketed already for obese patients with established cardiovascular disease as well as more recently for management of adolescent obesity with pediatric patients above 12 years and above. The addition of the MASH indication for Poviztra further strengthens the company's commitment to addressing complex metabolic diseases through innovative, science-led therapies while supporting physicians in improving long-term patient outcomes.